Jacobi Capital Management LLC grew its position in Novo Nordisk A/S (NYSE:NVO) by 241.3% during the 3rd quarter, HoldingsChannel reports. The firm owned 2,577 shares of the company’s stock after acquiring an additional 1,822 shares during the quarter. Jacobi Capital Management LLC’s holdings in Novo Nordisk A/S were worth $121,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in NVO. Chicago Partners Investment Group LLC lifted its stake in shares of Novo Nordisk A/S by 762.5% in the 2nd quarter. Chicago Partners Investment Group LLC now owns 3,131 shares of the company’s stock valued at $144,000 after purchasing an additional 2,768 shares in the last quarter. Schroder Investment Management Group acquired a new position in shares of Novo Nordisk A/S in the 2nd quarter valued at about $182,000. Legacy Financial Advisors Inc. lifted its stake in shares of Novo Nordisk A/S by 527.8% in the 3rd quarter. Legacy Financial Advisors Inc. now owns 3,886 shares of the company’s stock valued at $183,000 after purchasing an additional 3,267 shares in the last quarter. Stevens Capital Management LP acquired a new position in shares of Novo Nordisk A/S in the 2nd quarter valued at about $202,000. Finally, FineMark National Bank & Trust acquired a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at about $212,000. 6.84% of the stock is currently owned by institutional investors and hedge funds.

Several equities analysts recently commented on NVO shares. Zacks Investment Research raised Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research report on Tuesday, November 20th. UBS Group reissued a “buy” rating on shares of Novo Nordisk A/S in a research report on Monday, November 26th. Kepler Capital Markets reissued a “hold” rating on shares of Novo Nordisk A/S in a research report on Thursday, November 29th. Pareto Securities raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Monday, November 26th. Finally, ValuEngine raised Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research report on Saturday, October 27th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and six have given a buy rating to the company. Novo Nordisk A/S presently has a consensus rating of “Hold” and an average price target of $64.00.

Novo Nordisk A/S stock opened at $45.38 on Friday. The company has a market cap of $111.52 billion, a P/E ratio of 19.39, a P/E/G ratio of 2.40 and a beta of 0.75. Novo Nordisk A/S has a one year low of $41.23 and a one year high of $58.37.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Thursday, November 1st. The company reported $0.58 EPS for the quarter, hitting the consensus estimate of $0.58. The firm had revenue of $4.31 billion for the quarter, compared to analyst estimates of $4.11 billion. Novo Nordisk A/S had a return on equity of 81.50% and a net margin of 34.94%. Analysts predict that Novo Nordisk A/S will post 2.45 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Novo Nordisk A/S (NVO) Shares Bought by Jacobi Capital Management LLC” was first published by Watch List News and is the property of of Watch List News. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The correct version of this article can be read at https://www.watchlistnews.com/novo-nordisk-a-s-nvo-shares-bought-by-jacobi-capital-management-llc/2670909.html.

Novo Nordisk A/S Profile

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity.

See Also: Understanding Price to Earnings Ratio (PE)

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.